Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depression and analgesia.
For use during the induction and maintenance of general anesthesia.
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Ajou University Hospital, Suwon, Gyeongki-do, Korea, Republic of
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
Hôpital Roger Salengro, CHU, Lille, France
Service d'Anesthésie, Hôpital Foch, Suresnes, Ile De France, France
Service d'Anesthésie du Centre Clinical, Soyaux, Poitou-Charentes, France
Service d'Anesthésie Réanimation Chirurgicale, CHU Besançon, Besançon, Bourgogne-Franche-Comté, France
CMC Ambroise Paré, Neuilly-sur-Seine, Ile-de-France, France
Service d'Anesthésie-réanimation chirurgicale - Hôpital Trousseau, Paris, France
Erasme University Hospital, Bruxelles, Belgium
Military Hopital of Tunis, Tunis, Tunisia
Military hospital of tunis, Tunis, Mont Fleury, Tunisia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.